Bridgeway Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-30,000
| Closed | -$76K | – | 1394 |
|
|
2020
Q2 | $76K | Hold |
30,000
| – | – | ﹤0.01% | 1260 |
|
|
2020
Q1 | $38K | Buy |
+30,000
| New | +$61.2K | ﹤0.01% | 1238 |
|
|
2019
Q1 | – | Sell |
-5,490
| Closed | -$124K | – | 1431 |
|
|
2018
Q4 | $124K | Sell |
5,490
-3,750
| -41% | -$147K | ﹤0.01% | 1277 |
|
|
2018
Q3 | $510K | Buy |
9,240
+5,250
| +132% | +$335K | 0.01% | 1134 |
|
|
2018
Q2 | $285K | Hold |
3,990
| – | – | ﹤0.01% | 1260 |
|
|
2018
Q1 | $245K | Hold |
3,990
| – | – | ﹤0.01% | 1241 |
|
|
2017
Q4 | $503K | Hold |
3,990
| – | – | 0.01% | 1096 |
|
|
2017
Q3 | $546K | Hold |
3,990
| – | – | 0.01% | 1071 |
|
|
2017
Q2 | $569K | Sell |
3,990
-3,750
| -48% | -$580K | 0.01% | 1047 |
|
|
2017
Q1 | $1.42M | Sell |
7,740
-6,305
| -45% | -$707K | 0.02% | 685 |
|
|
2016
Q4 | $1.13M | Hold |
14,045
| – | – | 0.01% | 770 |
|
|
2016
Q3 | $1.08M | Sell |
14,045
-4,041
| -22% | -$324K | 0.02% | 767 |
|
|
2016
Q2 | $1.55M | Buy |
+18,086
| New | +$1.66M | 0.02% | 619 |
|
|
2015
Q3 | – | Sell |
-1,270
| Closed | -$1.21M | – | 1553 |
|
|
2015
Q2 | $1.21M | Sell |
1,270
-1,230
| -49% | -$1.01M | 0.02% | 712 |
|
|
2015
Q1 | $1.83M | Hold |
2,500
| – | – | 0.04% | 548 |
|
|
2014
Q4 | $1.99M | Hold |
2,500
| – | – | 0.05% | 516 |
|
|
2014
Q3 | $998K | Hold |
2,500
| – | – | 0.03% | 755 |
|
|
2014
Q2 | $675K | Buy |
+2,500
| New | +$537K | 0.02% | 950 |
|
Bridgeway Capital Management's TTPH Position: Q3 2020 in Review
Bridgeway Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 30,000 shares — an estimated $76K sold.
Bridgeway Capital Management first reported a position in TTPH in Q2 2014 and held it in 18 quarters. The position peaked at $1.99M in Q4 2014. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.
- Bridgeway Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Bridgeway Capital Management sold 30,000 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020, an estimated $76K.
- Bridgeway Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2014 and held it in 18 quarters.
- Bridgeway Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $1.99M in Q4 2014.
- 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.
Based on Bridgeway Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.